LLY - Lilly's olomorasib receives U.S. FDA 's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant adva
LLY - Lilly's olomorasib receives U.S. FDA 's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer